EcoDrugPlus

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSPREG00000021914
Gene Symbol: LOC103478877
3 Cross references
196 Possible Orthologues:

Matrix Metalloproteinase-18-Like

Ensembl ID : ENSPREG00000010537
Gene Symbol: LOC103476142
2 Cross references
194 Possible Orthologues:

Matrix Metalloproteinase-18-Like

Ensembl ID : ENSPREG00000010509
Gene Symbol: LOC108166865
2 Cross references
231 Possible Orthologues:

Matrix Metalloproteinase-9-Like

Ensembl ID : ENSPREG00000022793
Gene Symbol: LOC103467281
3 Cross references
202 Possible Orthologues:

Matrix Metalloproteinase-9-Like

Ensembl ID : ENSPREG00000013531
Gene Symbol: LOC103467158
3 Cross references
205 Possible Orthologues:

Matrix Metalloproteinase-9-Like

Ensembl ID : ENSPREG00000013643
Gene Symbol: LOC103467157
3 Cross references
205 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSPREG00000011138
Gene Symbol: MTOR
1 Cross references
215 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSPREG00000011061
Gene Symbol: MTOR
1 Cross references
215 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSPREG00000002511
Gene Symbol: MC1R
3 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSPREG00000022399
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSPREG00000000095
Gene Symbol: MTNR1A
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSPREG00000003031
Gene Symbol: MME
4 Cross references
233 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).